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Genomic DNA is organized around the double-stranded of B-form DNA, which is
both durable and flexible enough to store and pass on genetic information. Once freed
from the associations of an extended complimentary sequence, single stranded DNA and
RNA can adopt a vast array of stable secondary structure motifs, such as stem-loop,
pseudo-knots, and tetra-loops, ideal for its involvement in biological settings other than
as a store of genetic information. Originally, alkylating agents were used as "mustard
gas" and related chemical weapons in World War I. Alkylating agents, in general, can
react with one or two different 7-N-guanine residues and could potentially result in the
cross-linkage of DNA strands, preventing uncoiling of the DNA double helix leading to
cell death. More recent evidence show that guanine-rich nucleic acids can fold into
distinctive four-stranded conformers found in telomeric DNA repeats (i.e. TTAGGG),
also known as G-quadruplexes (G4), as well as in sequences in the promoter and other
regulatory regions of genes, especially those involved in cellular proliferation. Small
molecules that induce the formation of, and selectively bind to, G4 structures are of
interest for development as potential anticancer therapeutics. Novel 10-oxoanthracene
and substituted anthracenyl isoxazole esters (AIEs) were synthesized and characterized
based on NMR studies. To date, quarfloxin is the only G-quadruplex ligand from the
large number developed to progress to clinical evaluation. The synthesis, structural
characterization, and biological studies will be presented.
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1.1 Introduction
Gellert, Lipsett and Davies were the first to initially identify four-stranded helical
arrangements in fibers of guanosine monophosphate in 1962, which would have made
last year, 2012, the 50th anniversary of the birth of the quadruplex field.1 Genomic DNA,
which is organized around double-stranded B-form DNA, is both durable and flexible
enough to store and pass on genetic information. The standard of several secondary
structural motifs, helical B-form DNA, utilizes an anti-parallel arrangement of two
complimentary strands, stabilized by Watson-Crick base pairing (Figure 1). Once

Figure 1. The dimensions of duplex DNA and its base pair surface. Reprinted from
reference [6] with permission from the publisher.

freed from the associations of an extended complimentary sequence, single stranded
DNA and RNA can adopt a vast array of other stable secondary structure motifs, such as
stem-loop, pseudo-knots, and tetra-loops, ideal for its involvement in other biological
settings other than as a store of genetic information.2 Guanine-rich nucleic acids can fold

1

into distinctive four-stranded conformers found in telomeric DNA repeats (i.e.
TTAGGG) as well as in sequences in the promoter and other regulatory regions of genes,
especially those involved in cellular proliferation.

3, 4

The terminal 3’-telomeric 150–250

nucleotides single-stranded DNA can be induced and stabilized by certain small
molecules to form higher order G-quadruplex structures (Figure 2) that prevent the
interaction and regulation of the telomerase enzyme complex (Figure 3) in cancer cells

Figure 2. G-Quadruplex structure and G-quartet surface. Reprinted from reference
[6] with permission from the publisher.

(which is over-expressed in ~80–90%

4-6

), and thereby maintain telomere length

homeostatis (acting as a tumor promoter). Loss of the telomerase enzyme deprotects the
telomeres and initiates DNA damage-response mediated cell death since the enzyme can
no longer synthesize any further telomeric DNA repeats (Figure 3).3,

4, 7, 8

G-rich

sequences can utilize both the Watson-Crick and Hoogsteen faces of a guanine base to
self-associate in a hydrated environment containing cations to form extended four
2

stranded stacked structures termed G-quadruplex or G-quartet (Figure 2). The stability of
extended quadruplexes has fuelled research beyond biology into the development of nano
wires and sensors.2, 9, 10
Quadruplex formation at the telomeric single-strand overhang (Figure 3) may
itself be a DNA damage signal, producing responses analogous to those of other
mediators of telomere damage. The biological function of induced telomeric
quadruplexes remains to be fully clarified; an end-protective role has been suggested.11-13
However, to date, there is no direct evidence of a role for telomeric G-quadruplexes in
the functioning of telomeres in normal human cells.4 The working hypothesis is that the
ligand stabilizes telomeric DNA into quadruplex structures that inhibit the primer from
interacting as a single stranded species with the RNA template of telomerase. The
approach to target quadruplexes overrides the problem of telomerase resistance along
with inhibiting telomere-independent mechanisms of telomere maintenance in cancer
cells, making them more universally applicable than conventional telomerase inhibitors.2,
10

The discrete structures formed by defined numbers of guanosine nucleotides have
been subsequently termed quadruplexes, a name that is now applied to any structural
arrangement that incorporates at least two G-quartets (Figure 2)14 together with the
intervening sequences that hold the quartets together. For some years the quadruplex field
lay dormant, with the widespread belief that these structures were at best artifacts,
without functional biological significance. It has been only in the past 15 years that this
picture has been dispelled, with an ever-increasing number of studies indicating a
diversity of biological roles for quadruplex nucleic acids, at least some of which have
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therapeutic implications. This worldwide increase in activity has resulted in a tenfold
increase in the number of publications on quadruplexes; with over 400 in 2011. The more
general interest in quadruplexes has been shown by almost 12,000 citations in 2011 to the
quadruplex literature. 1, 15

Figure 3. Biological roles and structure of telomeres and the telomerase enzyme.
Reprinted from reference [6] with permission from the publisher.

The prevalence of G-quadruplex forming-sequences in the promoter regions of
genes involved in proliferation such as c-myc, c-kit, k-ras, bcl-2 and PDGF-A suggests

4

that it might be possible to use them to artificially regulate transcription of these genes,
and there is growing evidence that this is achievable. Even though G-quadruplex
formation has to compete with stable duplex DNA formed at promoter sites, it has been
shown that G-quadruplexes can be induced under conditions which mimic the
intracellular environment, and that their formation can have significant biological
consequences.3 Telomerase activity and G4-DNA formation in telomeres are significant
as they represent potential sites for small molecule drug interactions, in the treatment of
cancer, which may not have the ill effects of indiscriminate B-DNA binding. Small
molecules that can selectively bind to and stabilize these G-DNA structures would
represent a new class of potential anti-cancer therapeutics. 16-18
2.1 B-DNA Characteristics
2.1.1 DNA-Interactive Drugs
Another site in which drugs can interact is with DNA or deoxyribonucleic acid,
the polynucleotide that carries the genetic information in cells. Because DNA is so vital
to human functioning, and from the perspective of medicinal chemistry the overall shape
and chemical structure of DNA found in normal and abnormal cells is nearly
indistinguishable, drugs that interact with DNA are generally very toxic to normal cells.
Because the medical term for cancer is neoplasm, anticancer drugs may be referred to as
antineoplastic agents. Unlike the design of drugs that act on enzymes in a foreign
organism, there is little that is useful to direct the design of selective agents against
abnormal DNA. One feature of cancer cells that differentiates them from that of most
normal cells is that cancer cells undergo a rapid, abnormal, and uncontrolled cell division.
Genes coding for differentiation in cancer cells appear to be shut off or inadequately
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expressed, while genes coding for cell proliferation are expressed when they should not
be. Because these cells are continually undergoing mitosis, there is a constant need for
rapid production of DNA. Because of the correspondence of normal and abnormal DNA,
a compound that reacts with a cancer cell will react with a normal cell as well. However,
because of rapid cell division, cancer cell mitosis can be halted preferentially to that
found in normal cells where there is sufficient time for the triggering of repair
mechanisms. Tumor cells, however, are defective in their ability to undergo cell cycle
arrest or apoptosis in response to DNA damage. Cancer cells that cannot undergo cell
cycle arrest are sensitive to DNA damaging agents. In general, anticancer drugs are most
effective against malignant tumors with a large proportion of rapidly dividing cells, such
as leukemias and lymphomas. Unfortunately, the most common tumors are solid tumors,
which have a small proportion of rapidly dividing cells.19
2.1.2 Structure of DNA
The elucidation of the structure of DNA by Watson and Crick (Figure 1) was the
culmination of experimental results reported by a large number of scientists over several
years. All of this data was digested by Watson and Crick, who then proposed that two
strands of DNA are intertwined into a helical duplex which is held together by specific
hydrogen bonding between base pairs of adenine with thymine and guanine with cytosine
(Figure 4) to explain the results of Gulland and Chargar and that there base pairs were
stacked at 3.4Å distance, as observed in the X-ray photographs. Furthermore, righthanded rotation between adjacent base pairs by about 36° produces a double helix with
10 base pairs per turn. A model of the helix was constructed using dimensions and
confirmations of the individual nucleotides based on the structure of cytidine. The bases
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are located along the axis of the helix with sugar phosphate backbones winding in an
antiparallel orientation along the periphery (Figure 1). 19

Figure 4. Sites of alkylation on DNA bases. Reprinted from reference [21] with
permission from the publisher.

All of the bases of the DNA are on the inside of the double helix, and the sugar
phosphates are on the outside; therefore, the bases on one strand are close to those on the
other. Because of this fit, specific base pairing between a large purine base (either A or
7

G) on one chain and a smaller pyrimidine base (T or C) on the other chain are essential.
Hydrogen bonds between guanines and cytosine or adenine and thymine are more
effective than any other combination. Therefore, complementary base pairs (also called
Watson-Crick base pairs) form between guanines and cytokines or adenines and
thymines only, resulting in a complementary relation between sequences of bases on the
two polynucleotide strands of the double helix. As you might predict, because there are
three hydrogen bonds between G and C base pairs and only two hydrogen bonds between
A and T base pairs, the former are more stable. 19
The two glycoside bonds that connect the base pair to its sugar rings are not
directly opposite each other, and, therefore, the two sugar-phosphate backbones of the
double helix are not equally spaced along the helical axis (Figure 1). As a result, the
grooves that are formed between the backbones are not of equal size. The larger groove is
called the major groove and the smaller one is called the minor groove (Figure 1). One
side of every base pair faces into the major groove, and the other side faces into the minor
groove. The floor of the major groove is filled with base pair nitrogen and oxygen atoms
that project inward from their sugar phosphate backbones toward the center of the DNA.
The floor of the minor groove is filled with nitrogen and oxygen atoms of base pairs that
project outward from their sugar phosphate backbones toward the outer edge of the
DNA.19
2.1.3 Classes of Drugs That Interact with DNA
In general, there are three major classes of clinically important DNA-interactive
drugs: reversible binders, which interact with DNA through the reversible formation of
non-covalent interactions; alkylators, which react covalently with DNA bases; and DNA
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strand breakers, which generate reactive radicals that produce cleavage of the
polynucleotide strands. It is not yet clear what DNA sequences (genes) should be
targeted. Also, in traditional cancer chemotherapy significant amounts of DNA damage
are required to elicit the cell killing that is necessary for effective anticancer drugs. 19
Alkylating agents are a ubiquitous family of reactive chemicals that transfer alkyl
carbon groups onto a broad range of biological molecules, thereby altering their structure
and potentially disrupting their function as Lippard et. al showed with cisplatin20 (Figure
5). Alkylating agents are generally unavoidable owing to their abundant presence in the

Figure 5. Structure of the damaged DNA duplex
environment and within living cells. Major sources of external alkylating agents include
the constituents of air, water and food, such as biological byproducts (for example,
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abiotic plant material) and pollutants (for example, tobacco smoke and fuel combustion
products). Internally, alkylating agents can arise as byproducts of oxidative damage or
from cellular methyl donors such as S‑adenosylmethionine. Owing to the cytotoxic,
teratogenic and carcinogenic effects that are caused by alkylation damage, alkylating
agents pose considerable threats to human health. In spite of this, certain toxic alkylating
agents are commonly used systemically as chemotherapeutic drugs in cancer patients,
with the goal of killing cancer cells. Consequently, although alkylating agents can induce
cancer, they are also used to treat cancer. On the basis of the double-edged properties of
alkylating agents, a greater understanding of the cellular factors that determine biological
outcome in response to alkylation damage is particularly relevant for both cancer
prevention and cancer therapy, in addition to general human health. The biological
response to alkylating agents can be complex owing to the variety of lesions that are
introduced by a single alkylating agent in combination with the diversity of cellular repair
mechanisms and response pathways that can be elicited on alkylation damage.21
2.1.4 DNA Alkylators
Alkylating agents react with the ring nitrogens (N) and extracyclic oxygen (O)
atoms of DNA bases (Figure 1) to generate a variety of covalent adducts that range from
simple methyl groups to complex alkyl additions. The pattern of DNA lesions generated
by an alkylating agent depends on the number of reactive sites within the alkylating agent
(monofunctional versus bifunctional), its particular chemical reactivity (SN1-type versus
SN2-type nucleophilic substitution) (Scheme 1a), the type of alkyl group addition (methyl
or chloroethyl and so on) and the DNA substrate (double-stranded or single-stranded).
Monofunctional alkylating agents contain one active chemical moiety for the
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modification of a single site in DNA, whereas bifunctional alkylating agents contain two
reactive groups that can bond to separate DNA bases to form interstrand crosslinks.
Whereas SN2-alkylating agents mainly target ring nitrogen atoms in DNA bases, SN1alkylating agents can modify these nitrogens plus the extracyclic oxygen groups (Figure
6). Notably, nearly all chemotherapeutic alkylating drugs that are currently used in the
clinic are SN1-type and they can be either mono-functional or bi-functional (Figure 6). 21
Owing to the high nucleophilic reactivity of the N7-position of guanine in DNA,
most monofunctional methylating agents induce the formation of N7-methyl guanine
(7meG) as the predominant methylation adduct, which accounts for 60–80% of the total
alkylation lesions in DNA with 3meA being second accounting for 10–20% (Figure 4).
By itself, 7meG does not possess any mutagenic or cytotoxic properties with 3meA lesion
being highly cytotoxic. Amongst the oxygen atoms of DNA, the O6-position of guanine
is a major site of methylation by SN1-type alkylating agents for generating O6methylguanine (O6meG) (Figure 4). Even though O‑alkyl lesions are generated to a
much lesser extent than N‑alkyl adducts, the induction of O6meG lesions by alkylating
agents is of great biological relevance because O6meG can readily mispair with thymine
during DNA replication to cause many of the mutagenic and cytotoxic biological effects
of alkylating agents. Alkylating agents can also modify other nitrogen and oxygen atoms
in DNA to generate additional toxic and mutagenic lesions. However, these lesions are
observed at tenfold to 100‑fold lower levels than the lesions mentioned above and
represent a small proportion of total alkylation adducts. 21
Several monofunctional SN1-methylating agents are currently used as anticancer
drugs; these include the triazine family of compounds such as dacarbazine, procarbazine
11

and temozolomide, as well as the nitrosourea compound streptozotocin (Figure 6). Owing
to their chemical reactivity as monofunctional SN1-methylating agents, these

Figure 6. DNA lesions induced by alkylating agents. Reprinted from reference [21]
with permission from the publisher.

chemotherapeutic alkylating agents produce substantial levels of 7meG, 3meA and
O6meG as the primary alkylated DNA adducts. The chloroethylating agents represent
another major class of monofunctional alkylating agents that react with DNA at a similar
specificity to SN1-methylating agents except with the addition of a chloroethyl group.
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Most nitrosourea compounds that are used in the clinic are chloroethylating agents that
can modify the N7 and O6-positions of guanine to generate chloroethyl adducts (Figure
6). Importantly, O6-chloroethyl guanine (O6Cl-ethylG) adducts undergo rapid chemical
rearrangement to react with nearby cytosine bases to generate guanine–cytosine (G–C)
interstrand crosslinks that are highly cytotoxic. 21
Bifunctional alkylating agents have similar reactive properties to monofunctional
alkylating agents but contain two active moieties that can react with separate bases of

a.)

b.)

Scheme 1. Mechanisms of nucleophilic substitution. a.) Nucleophilic substitution
mechanism. b.) Mechanism for alkylation of DNA
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DNA to form interstrand crosslinks in addition to monoadducts (Figure 6). The nitrogen
mustards and aziridine compounds are two major classes of bifunctional alkylating drugs
used for cancer treatment that can crosslink DNA through an aziridinium-ring
intermediate. Nitrogen mustard compounds react readily with N7-guanine and, to a lesser
extent, with N3-adenine and N7-adenine to form bulky N-monoadducts. These adducts
can subsequently react with another base to form guanine–guanine (G–G) and guanine–
adenine (G–A) interstrand crosslinks (Figure 6).
Depending on their position in DNA, the different base adducts that are
introduced by alkylating agents can compromise genome integrity by inducing
mutagenesis (thereby promoting cancer induction) and/or by blocking essential biological
processes such as DNA replication and transcription (which could potentially lead to cell
death). Moreover, certain lesions can also be processed into clastogenic and cytotoxic
products that can engage other DNA repair pathways or that can induce programmed cell
death. It is important to note that other biological molecules are also subject to alkylation
damage, including RNA, protein, lipids and mitochondrial DNA. Thus, a single
chemotherapeutic alkylating agent can modify a variety of biological molecules to
generate a range of lesions that can elicit a number of biological effects. 21
3.1 G-quadruplex Structure
3.1.1 The G-quadruplex backbone
The fundamental unit of the G-quadruplex is the G-quartet, which is built from
the association of four guanine bases in a cyclic motif (Figure 4). Utilizing both
Hoogsteen hydrogen bonding and Watson–Crick faces, the tetrad is a square shaped unit
stabilized by eight hydrogen bonds (N1–O6, N2–N7) with the O6 atoms pointing
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centrally into the ring to form an anionic anti-prismatic bipyramidal cage (Figure 7). The
planar tetrad can further associate to form extended 3D structures exploiting their large
aromatic π-surfaces, which are bigger than the Watson-Crick base pairs. The square
aromatic surface is then further stabilized by association of metal ions that intercalate into
the central channel (Figure 7), and this difference constitutes the basis for designing Gquadruplex specific ligands.5, 22-23

Figure 7. Guanine Base Pairing & Quadruplex Structures. Reprinted from reference
[14] with permission from the publisher.

3.1.2 Topology for potential G-quadruplex binders
G-quartets can stack on top of each other to form four-stranded G-quadruplexes
(Figure 7). These structures exhibit extensive structural diversity and polymorphism
relative to duplex DNA. In general, structural polymorphism arises mostly from the
nature of the loop, such as variations of strand stoichiometry, strand polarity, glycosidic
torsion angle(s), and the location of the loops that link the guanine strand(s). Meanwhile,
the solution environment, such as the presence of metal ions, ligands, or molecular
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crowding conditions, may also influence the topology of quadruplex.5 G-quadruplexes
can be folded from a single G-rich sequence intra-molecularly (parallel) or by the
intermolecular association of two (dimeric or bimolecular, antiparallel or parallel) or four
(tetrameric or tetramolecular, parallel) separate strands.5, 24 The telomeric G-quadruplexforming sequence structures has been summarized by Ou et al. (see Figure 8).5 The
stacked tetrads remain planar, with a similar rise and twist and the direction (5’ to 3’) that
the phosphodiester backbone runs can vary. In duplex DNA and RNA, an anti-parallel
arrangement is required, while quadruplexes can accommodate any combination of
directions, giving rise to both parallel and anti-parallel alignments22 (Figure 9a). For
example, two intramolecular G-quadruplex structures have been identified from the
human telomeric sequence as the basket-type and propeller-type, depending on the
incubation conditions (Figure 9).24

Figure 8. G4-DNA topologies and diversities. Reprinted from reference [6] with
permission from the publisher.
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Variations in strand polarity also affect the location of the linkers, or loops
between G-rich segments. As shown in Figure 9a, parallel G-strands require a connecting
loop to link the bottom G-tetrad with the top one, leading to propeller-type loops. In
general, the sequence and size of the loops play an important role in determining the
topology and stability of quadruplexes. In addition, loop residues can themselves form
stacking and hydrogen bonding interactions, further stabilizing (or destabilizing) Gquadruplex folds, while longer linker lengths favor antiparallel backbone alignments,
which may also contain guanine residues that could be expected to form part of a guanine
tetrad.5 A recent molecular dynamics simulation has revealed that the sequences of the
connecting loops in quadruplexes are the major contributors to quadruplex flexibility and
are the potential sites for drug binding. 5, 16-18, 22-23, 25
The central coordinated charged cavity can accommodate a variety of metal
cations of different radii that strongly influences not only the final folded topology of the
stacked quadruplex but also its stability. The metal ion stabilizing influence is linked to
the increasing radii from Li+ < Na+ < K+ with potassium being optimal, and
dramatically increasing G-quadruplex stability. The hole between G-tetrads is well suited
to coordinating cations of this size because the two planes of tetrads are lined by eight
carbonyl O6 atoms (with strong negative electrostatic potential) that create a central
negatively charged channel inside the G-tetrad stack (Figure 9b).5, 16-18, 22-25
In solution, many quadruplex-forming sequences adopt multiple folding
topologies depending on the length of individual G-quartets, loop composition and size,
and the type of cation. It has been reported that human genes contain as many as 376,000
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quadruplex-forming sequences.26 Databases used in screening and identifying Gquadruplex structures are very common. With the increasing number of quadruplexes

Figure 9. Basic G-Quadruplex building blocks. Reprinted from reference [6] with
permission from the publisher.

reported in genomic studies, drug design must be directed not only to differentiating
between duplex and quadruplex DNA species, but also to recognizing different
quadruplex species. The area of G-quartets, loop regions, groove dimensions, and the
negative electrostatic potential of the anionic backbone and the central channel of Gquadruplexes are critical elements that need to be considered in order to improve the
binding selectivity of drug candidates.5
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4.1 G-quadruplex Binding Ligands
4.1.1 Quadruplex DNA Small Molecule Interactions
Small molecules that induce the formation of, and/or selectively bind to, Gquadruplex structures are of interest for development as potential therapeutic agents,
particularly in the anticancer therapeutic area. Of the quadruplex binding molecules
identified to date, many are based on core functionalized polycyclic heteroaromatic
systems such as acridines, anthraquinones, perylenes or porphyrins (Figure 10). A few of
these have been shown to produce G-quadruplex-related biological effects even though
their physicochemical features are conventionally non-drug-like. A common approach to
G-quadruplex ligand design involves taking these relatively large aromatic ring systems
as a starting-point on the basis that they can interact with the terminal G-quartets of a
quadruplex through π–π interactions (end-stacking). Thus, the first small molecule
reported to bind to G-quadruplex DNA was an anthraquinone derivative. Following this,
molecules containing similar structural motifs such as fluorenones and acridines were
described. As aromatic groups alone are insufficient to confer high binding affinity, and
their hydrophobicity reduces water solubility, they have frequently been functionalized
with one or more cationic side chains to improve solubility and enhance potential
bonding interactions with backbone phosphates and functional groups in the unique loops
and grooves found in G-quadruplex structures.3, 27
In addition, several G-quadruplex-targeting ligands designed to date have shape
characteristics that minimize duplex DNA interaction. This design strategy is apparent in
the acridine derivative BRACO-19, the first synthetic G-quadruplex ligand to have
significant selectivity compared to duplex DNA. Other polycyclic G-quadruplex-binding
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ligands include TMPyP4 (a cationic porphyrin), telomestatin (a cyclic oxazole-containing
natural product from Streptomyces anulatus), and RHPS426 (a polycyclic acridine)

Figure 10. Quadruplex-DNA binding molecules

(Figure 6). The large planar surfaces of these compounds, their high molecular weights
(600 or above) and lipophilicity, and (for some) their significant charge and poor water
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solubility indicate that they are mostly non-drug-like and deviate from the Lipinski Rule
of Five in terms of their potential for oral bio-availability.3 More recent reports have
demonstrated that non-conjugated compounds that are synthetically more accessible than
telomestatin can have potency against telomerase and quadruplex selectivity. Many
quadruplex-binding ligands have been reported subsequently, although relatively few
have been evaluated in cell-based assays, or even with reliable in vitro telomerase
assays.4, 27 To date, quarfloxin (Figure 10) is the only G-quadruplex ligand from the large
number that have been developed to have progressed to clinical evaluation.3
G4-DNA binding molecules have been the subject of much study in the new
millennium with many examples showing a high degree of selectivity and binding
stability.28-33 However, daunomycin (Figure 10) is already a compound used in general
medical practice to treat cancer and has appreciable G4-DNA binding affinity. This data
suggests that the antitumor activity of daunomycin may in fact be due, in some part, to
quadruplex stabilizations in genomic DNA.
It is proposed that designing the optimal G4-DNA binder must also contain some
mimic of a bio-molecule (e.g. peptide bonds) so as to minimize recognition as an antigen,
quick metabolism, and excretion from the body before it can exert its function. Because
of the compact nature of duplex DNA a G4-DNA binding ligand would need to be preorganized so that unfavorable steric interactions would keep the required large planar
group from intercalating between the base pairs. Figure 11 illustrates the isoxazole
systems, containing an anthracene or anthrone ring system with a hydrogen bond
acceptor ethyl isoxazole ester, which could serve the purpose addressing all of the
important factors (i.e. pre-organization, hydrogen bond acceptor/donor, and small size).
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Figure 11. Combining functionalities to form a selective G4-DNA ligand.

4.1.2 Structural Features of a non-B-DNA binder
The anthracene isoxazole ester system (AIE) (Figure 11) was designed so as not
to intercalate B-DNA because of the small distance between the isoxazole and anthracene
moieties. AIE was designed to mimic the behavior of guanines and stabilize or induce the
G-quadruplex structure, which in turn can inhibit telomerase activity. The essential
pharmacophore for telomerase inhibition is a large aromatic core that favors planar π-π
stacking interactions with the G-tetrads. Positively charged side chains that interact with
the DNA grooves, can exploit the central electronegative channel to enhance binding.
Electrostatic interactions between ligand side chains and DNA phosphates play a major
role in the formation and stabilization of G-quadruplex structures and in selecting its
topology; so the presence of a cationic center on side chain is favorable for optimal
electrostatic interactions with negative charges on the phosphate backbone of DNA. The
size of the side chain is also important, and small tether length has better inhibitory
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activity. Existence of an atom which can form a hydrogen bond is favorable, especially
an oxygen atom..2
Also, Neidle had previously shown that there were several possible binding
modes (Figure 12) for amidoanthracne-9, 10-diones to quadruplex DNA based on

Figure 12. G-quadruplex small molecule stabilization binding modes. Reprinted
from reference [54] with permission from the publisher.
substitution using molecular modeling,33-35 stopped-flow kinetics,36 thermal DNA
melting,35 and X-ray crystalography.35 Hurley showed that the porphyrns 5,10,15,20tetra-(N-methyl-2-pyridyl)porphine

(TMPyP2)

and

5,10,15,20-tetra-(N-methyl-2-

pyridyl)porphine (TMPyP4) (Figure 10), bind G-quadruplex structures externally atop the
G-tetrad.37 Furthermore, Hurley and Neidle described in a review how quindoline and
Berberine (related plant alkaloid) are classic G-quadruplex binding agents with their
derivatives showing significant anti-proliferative properties in cancer cell lines; as well
as, the two current standards in quadruplex binding: telomestatin and tri-substituted
isoalloxazines.14 Given these findings we felt the next step was to use computer based
molecular modeling to determine which mode of binding best suited the AIE system.
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5.1 10-Methoxy anthracene isoxazole ester synthesis
Scheme 1 outlines the modified synthesis method from the oxime used by Natale
and coworkers 38-40 to generate anthracene isoxazole ester 1. Initial bromination of 2 was
successful in methylene chloride with a slight modification from Cakmak and
coworkers41. Subsequent methylation of 3 was achieved with the addition of a 1.2-fold
excess of sodium methoxide in situ in warm DMF yielding 4 in good yields.

Scheme 2. Method for the formation of anthracene isoxazole ester 1
Oxime formation from the aldehyde of 4 with hydroxyl amine hydrochloride and
sodium acetate in refluxing DMF afforded the oxime 5. Formation of the oximinoyl
chloride intermediate 6 was performed using recrystallized N-Chlorosuccinamide (from
benzene) and CHCl3 at room temperature (yield not calculated). Finally, 6 was reacted
with triethylamine and ethyl acetoacetate in absolute ethanol to give the final product 1 in
92% yield after two steps.
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6.1 Anthrone isoxazole ester
Scheme 2 outlines the anthrone synthesis combined with the method used by
Natale and coworkers40 to generate symmetrical anthrone isoxazole ester 13. Subsequent
oxime formation from the aldehyde 8 was achieved with the addition of a 2.0 eq. excess
hydroxylamine hydrochloride and a 3.5 eq. excess of sodium acetate in THF:EtOH:H2O
until the no slurry was observed yielding 9.

Scheme 3. Method for the formation of anthrone isoxazole ester 13
Formation of the oximinoyl chloride intermediate 10 was performed using
recrystallized N-Chlorosuccinamide (from benzene) and dry CHCl3 at 45oC (yield not
calculated).

Oximidoyl chloride 10 was reacted with sodium ethoxide and ethyl

acetoacetate in absolute ethanol to give the product 11 in great yields after two steps. The
subsequent chlorination of 11 was achieved with a slight modification from the procedure
of Natale and coworkers40. Finally, another chlorination reaction with NCS in DMF gave
the final product 13.
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The regiochemistry of the final product 13 was determined by 2D correlation
spectroscopy or HSQC (Heteronuclear Single Quantum Coherence). Figure 13 illustrates
an example of how the proton assignments and regiochemistry were made from a HSQC
experiment of anthrone product 13. The numerical labels such as 8.31, 182.5, and 0.05
indicate protons correlated, carbons correlated and intensity. The peri-aryl protons H-9 &
H-19 are easily spotted at ppm 7.26 by their strong J2 coupling and chemical shift which
have a strong correlation to the tertiary carbon at ppm 62. It is clear that H-12 and H-16
are down field at ppm 8.31 correlating to the carbonyl carbon ppm 182.
7.1 Anthrone isoxazole ester crystal structure
The crystal structure of ethyl 3-(9-chloro-10-oxo-9, 10-dihydroanthracen-9-yl)-5methylisoxazole-4-carboxylate (13) was obtained. It possesses similar bond lengths and
angles as the previously reported isoxazole ester, ethyl 3-(10'-chloro-9'-anthracenyl)-5methyl-4-isoxazolecarboxylate. The anthrone is virtually planar, and adopts a shallow
boat conformation, as evidenced by the absolute sum of the six intra- B-ring dihedral
angles (40.9081°). The compound adopts a conformation wherein the isoxazole ring is
roughly orthogonal (torsion angle: C60 C56 C62 C63, 67.0°) to the anthrone ring (see
Figure 14) with the isoxazolyl ester carbonyl O(7) being located within 3.3Å of the
anthrone carbon C(31). Furthermore, in the unit cell the anthrone H(6) of one molecule of
the title compound is within 3.3Å of C(22) of the second molecule at a dihedral angle of
~30o, consistent with an edge-to-face π-stacking interaction. This conformation could be
a vital factor in the study of the binding of this species in the drug-DNA complex in
further research.
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Figure 13: HSQC of 13, shows proton shift, carbon shift, and correlation intensity.
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Figure 14: ORTEP diagram of 13.
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8.1 Experimental Section
All starting chemicals were purchased from Aldrich Chemical Company and used
without any further purification unless otherwise indicated. Solvents were reagents grade
and dried just prior to use by standard methods. Melting points were determined in open
capillary tubes on a Melt-Temp apparatus and are uncorrected. High resolution mass
spectra (HRMS) were obtained using a Micromass electrospray ionization (ESI)/time-offlight mass spectrometry (LCTOF). NMR spectra for preliminary identification of
products were collected on a Bruker AC200 (UltraShield™ 400MHz) using X-Win NMR
(3.1). Mass spectrometer samples were introduced using a Waters model 2690
separations module HPLC fitted with a C-18 reversed phase column (2.1 mm i.d., 5 cm).
Flash chromatography was performed using Sorbent Technologies standard silica gel (60
Å) with reagent grade solvents using in house compressed air.
8.1.1 Method of 10-methoxy anthracene isoxazole ester formation
To a suspension of 2 (4.175g, 20.244mmol; Sigma-Aldrich, 97%) in methylene
chloride (120mL) was added Br2 (1.1 eq., 1.2mL, 23.428mmol) diluted in methylene
chloride (5mL) drop wise over 5 minutes. The reaction was covered with septa and guard
column (charged with CaCl2 and NaOH(s)) and allowed to stir at 63°C until TLC showed
no starting material remained (ca. 5 hours). Once the solution reached room temperature,
25g Na2SO3 in 200mL H2O was added to neutralize excess Br2. The solution was then
transferred to a separatory funnel, washed with 50mL metheylene chloride and the
organic layer extracted and dried with sodium sulfate and concentrated under reduced
pressure to yield 3 (Rf=0.34, 10:1 Hex/EtOAc, Figure 15). Recrystallized from
chloroform/hexanes.
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10-Bromoanthracene-9-carbaldehyde (3). (83%) 1H NMR(CDCl3) δ 11.52 (s, 1H),
8.90-8.93 (m, 2H), 8.69-8.71 (m, 2H), 7.64-7.74 (m, 4H).

13

C NMR (CDCl3) δ 193.28,

131.94, 131.82, 130.29, 129.02, 128.91, 128.29, 128.29, 127.47, 127.40, 125.70, 123.84.
mp 205-208°C. Spectral data are in accord with those reported previously.42-43
The brominated aldehyde 3 (0.150g, 0.5261mmol) was taken up in 2mL of DMF
(dried over sieves) under a nitrogen atmosphere. Freshly distilled methanol (1.2 eq.,
0.03mL) was added via syringe. Sodium hydride (1.2 eq., 0.0253g) was added with a
water condenser. The solution was allowed to stir at 60°C for 3.5 hours under an argon
atmosphere. Once the solution cooled to room temperature, 50mL DI H2O and 50mL
diethyl ether was added and allowed to stir for 15 minutes. The solution was transferred
to a separatory funnel and washed with 50mL diethyl ether. The combined organic layers
were washed with 50mL Brine, dried over sodium sulfate and concentrated under
reduced pressure. The solid was taken up in minimal methylene chloride and ran on a
prepared hexanes silica column in 12:1 (Hexanes:EtOAc) until all desired product 4 was
collected (Figure 16).
10-Methoxyanthracene-9-carbaldehyde (4). (85%) 1H NMR (CDCl3) δ 11.49 (s, 1H),
9.09 (d, J=9.03, 2H), 8.42 (d, J=8.66 Hz, 2H), 7.70-7.74 (m, 2H), 7.58-7.62 (m, 2H), 4.22
(s, 3H). 13C NMR (CDCl3) δ 191.93, 159.18, 134.12, 133.89, 129.34, 127.23, 125.60,
124.21, 123.96, 123.11, 121.17, 63.96. MS (EI) m/z 236 (22.37, M+), 237(100, M+1),
238 (18.80, M+2). (Rf=0.46 4:1:1 Hex/EtOAc/DCM).
To a suspension of 4 (0.1659g, 0.6302mmol) in 200 proof ethanol (23mL) was
dissolved hydroxylamine hydrochloride (2.5eq, 0.1095g, 1.58mmol) and pyridine (20eq,
1mL, 12.4mmol) The reaction was covered with a septa and water condenser and let
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reflux (ca. 80°C) for 2 days under an argon atmosphere. The solution was first
concentrated under reduced pressure then transferred to a separatory funnel and washed 1
x 50mL 1N HCl (cold) and the combined aqueous layers washed 2 x 20mL CH2Cl2, dried
over sodium sulfate, filtered, and the solvent removed under vacuum. The solid was then
chromatographed on a prepared hexanes

silica column starting with

8:1:1

Hex/EtOAc/DCM, 4:1:1, and finally 2:1:1 until desired product 5 was all collected
(Figure 17).
10-Methoxyanthracene-9-carbaldehyde oxime (5): (79%) 1H NMR (CDCl3) δ 9.20 (s,
1H), 8.45-8.46 (m, 2H), 8.36-8.38 (m, 2H), 7.53-7.60 (m, 4H), 4.17 (s, 3H). 13C NMR
(CDCl3) δ 154.22, 148.95, 131.20, 126.90, 125.36, 125.29, 124.29, 122.72, 119.83,
63.45. MS (EI) m/z 234 (100, M-H2O), 235 (28.54, M-H2O)+, 252 (38.87, M+1).
(Rf=0.34, 4:1:1 Hex/EtOAc/DCM).
The starting oxime 5 (0.0905g, 0.3601mmol) was taken up in 10mL of
chloroform at room temperature, to which the solution was added Et3N (1.23eq, 0.045g)
and recrystallized NCS (1.45eq, 0.0697g, .52198mmol) over 5 minutes. The solution was
allowed to stir at room temperature under argon for 2 hours. The organic layer was
washed with 1 x 100mL DI H2O, then the aqueous layer washed 1 x 20mL CHCl3, dried
with sodium sulfate, filtered, and the solvent removed under reduced pressure to yield 6.
The intermediate 6 was purified only through extractive isolation using water and CHCl3
and taken on to the next reaction as is. To a solution of 6 in absolute ethanol (20mL) was
added 1.75 equivalents of ethyl acetoacetate (0.0741g, 0.6314mmol) and 1.91eq. Et3N
(0.0696g, 0.6878mmol). The mixture was allowed to stir at 40°C under argon for 30
hours until TLC in 4:1:1 Hex/EtOAc/DCM revealed all nitrile oxide had been consumed.
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Finally, the ethanol was removed via rotary evaporation and the solid dissolved in CHCl3,
washed 2 x 50mL Brine, and the aqueous layer washed 1 x 20mL CHCl3, dried sodium
sulfate, and concentrated under reduced pressure. The solid was then chromatographed
using 1:1 Hex/EtOAc, then 1:2 and flushed with EtOAc until all desired product 1
(Figure 18) was collected.
N-hydroxy-10-methoxyanthracene-9-carbimidoyl chloride (6): Was not purified,
carried on through in situ procedure only. 1H NMR(400 MHz, CDCl3) δ 8.36 (d, J=8.78
Hz, 2H), 8.31 (d, J=8.78, 2H), 7.70 (t, J=15.06, 7.40 Hz, 2H), 7.60 (t, J=15.31, 8.28 Hz,
2H), 4.20 (s, 3H).
Ethyl

3-(10-methoxyanthracen-9-yl)-5-methylisoxazole-4-carboxylate

(1).

32%.

(Rf=0.17 1:2 Hex/DCM, Rf=0.49 4:1:1 Hex/EtOAc/DCM). 1H NMR(400 MHz, CDCl3)
δ 8.37 (d, J=8.77 Hz, 2H), 7.65 (d, J=8.53 Hz, 2H), 7.51 (t, 2H), 7.43 (t, 2H), 4.20 (s,
3H), 3.71 (q, J=7.15 Hz, 2H), 2.93 (s, 3H), 0.35 (t, J=7.15 Hz, 3H).
8.1.2 Method of anthrone isoxazole ester formation
To a suspension of 8 (4.0g, 19.39mmol; Sigma-Aldrich, 97%) in THF: Ethanol:
H2O (54mL: 27mL: 27mL) was dissolved sodium acetate (3.5 eq., 5.57 g, 67.89mmol)
and hydroxylamine hydrochloride (2eq, 2.69g, 38.71mmol). The reaction was covered
with a septa and let stir at room temperature until TLC showed no starting material
remained (ca. 49 hours). The solution was then transferred to a separatory funnel and
washed 4 x 200mL Brine and the combined aqueous layers washed 2 x 50mL CHCl 3,
dried over sodium sulfate, filtered, and the solvent removed under vacuum to yield 9
(Figure 19).
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Anthracene-9-carbaldehyde oxime (9). 99%. (Rf=0.53 4:1:1 Hex/EtOAc/DCM), 1H
NMR (CDCl3) δ 9.22 (s, 1H), 8.51 (s, 1H), 8.42 (d, J=8.66 Hz, 2H), 8.03 (d, J=8.16 Hz,
2H), 7.50-7.59 (m, 4H).

13

C NMR (CDCl3) δ 148.98, 131.30, 130.21, 129.35, 128.86,

128.81, 126.78, 126.42, 125.39, 124.97, 123.64.
The starting oxime 9 (4.667g, 21.09mmol) was taken up in 120mL of chloroform
at room temperature, to which a solution of pyridine (10mol%, 2.00mL) and
recrystallized NCS (1.1eq, 3.098g, 23.20mmol). The solution brought to 45ºC for 3.5
hours then cooled to room temperature. The organic layer was washed with 4 x 200mL
Brine and 2 x 150mL H2O, then the aqueous layer washed 2 x 150mL CHCl3, dried with
sodium sulfate, filtered, and the solvent removed under reduced pressure to yield 10. The
intermediate was purified only through extractive isolation using brine and CHCl 3 and
taken on to the next reaction as is. To a solution of 10 in absolute ethanol (100mL) was
added 1.4 equivalents of ethyl acetoacetate (3.8425g, 29.53mmol). In a separate round
bottom was added 50mL absolute ethanol and 1.018g Na(s). Once the sodium
dissociation had completed, the warm solution was added to the nitrile oxide and the
mixture was allowed to stir at room temperature under argon for 21.5 hours until TLC in
4:1 Hex/EtOAc revealed all 10 had been consumed. Finally, the ethanol was removed
via rotary evaporation and the solid dissolved in CHCl3, washed 4 x 200mL Brine, and
the aqueous layer washed 2 x 150mL CHCl3, dried sodium sulfate, and concentrated
under reduced pressure. The solid was then chromatographed using 4:1 Hex/EtOAc to
give desired product 11 (Figure 20).
N-hydroxyanthracene-9-carbimidoyl chloride (10): Was not purified, carried on
through in situ procedure only
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Ethyl 3-(anthracen-9-yl)-5-methylisoxazole-4-carboxylate (11). 93%.1H NMR (400
MHz, CDCl3) δ 8.59 (s, 1H), 8.06 (d, J=7.91, 2H), 7.66 (d, J=8.16 Hz, 2H), 7.41-7.50 (m,
4H), 3.70 (q, J=7.15 Hz, 2H), 2.93 (s, 3H), 0.33 (t, J=7.15 Hz, 3H). 13C NMR (CDCl3) δ
176.16, 161.52, 160.44, 131.01, 130.82, 128.64, 128.45, 126.25, 125.44, 125.21, 122.75,
111.37, 60.02, 13.41, 12.80. Spectral data are in accord with those reported previously3839

.
Compound 11 (0.300g, 0.905mmol) was taken up in 10mL DMF to which was

added a solution over 10 minutes of N-Chlorosuccinimide (NCS) (1.2eq, 0.1461g,
1.094mmol) dissolved in 5mL DMF. The solution was brought to 43ºC and let stir for 4
hours whereupon the solution was poured into 50mL ice/water which was allowed to stir
for 1 hour with the product 12 (Figure 21) precipitating out. Product was filtered and
washed with 2 x 25mL DI water.
Ethyl 3-(10-chloroanthracen-9-yl)-5-methylisoxazole-4-carboxylate (12). 96%.1H
NMR (400 MHz, CDCl3) δ 8.59 (d, J=8.91 Hz, 2H), 7.59-7.66 (m, 4H), 7.46-7.50 (m,
2H), 3.72 (q, J=7.15 Hz, 2H), 2.93 (s, 3H), 0.39 (t, J=7.15 Hz, 3H). 13C NMR (CDCl3) δ
176.29, 161.28, 160.15, 131.13, 131.00, 128.30, 126.67, 126.52, 125.84, 125.04, 122.60,
111.43, 60.15, 13.43, 12.91. Spectral data are in accord with those reported previously38.
The chlorinated anthracene 12 (0.3312g, 0.905mmol) was taken up in 5mL DMF
to which was added a solution over 10 minutes of N-Chlorosuccinimide (NCS) (1.2eq,
0.1451g, 1.087mmol) dissolved in 5mL DMF. The solution was brought to 30ºC and let
stir for 43 hours whereupon the solution was poured into 50mL ice/water which was
allowed to stir for 1.5 hours with the product precipitated out. Product was filtered and
washed with DI water. The solid was dissolved in minimal CH2Cl2 and placed on a wet
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silica column prepared with hexanes. The solvent polarity increased using a stepwise
elution of 10:1, 6:1, and finally 4:1 until all 13 (Figure 22) was collected.
Ethyl

3-(9-chloro-10-oxo-9,10-dihydroanthracen-9-yl)-5-methylisoxazole-4-

carboxylate (13). 29%, (Rf=0.28, 4:1 Hex/EtOAc), 1H NMR(CDCl3) δ 8.38 (dd, J=1.38,
7.65 Hz, 2H), 7.51-7.61 (m, 4H), 7.34 (dd, J=1.13, 7.91 Hz, 2H), 3.56 (q, J=7.15 Hz,
2H), 2.70 (s, 3H), 0.65 (t, J=7.03 Hz, 3H);

13

C NMR(CDCl3) δ 182.58, 178.50,162.69,

159.76, 142.41, 133.92, 129.85, 129.13, 127.84, 127.58, 107.92, 62.51, 60.43, 13.78,
13.47. MS (EI) m/z 346(100, M-Cl), 347(28.33, M-Cl)+, 348(8.42, M-Cl)+2.
9.1 Future Direction
Many high affinity ligands have been synthesized and studied in previous reports
but it is proving elusive to structurally determine ligand interactions in a routine manner.
Currently the application of crystallographic techniques is providing us with the most
comprehensive picture of ligand binding interactions; however the validity of the model
is in some ways compromised by crystal packing forces within a crystalline lattice. Even
within these constraints, it is clear that the stacked G-quadruplex core remains intact with
little scope for the intercalation of planar ligands. The diverse ranges of G-quadruplex
forming sequences identified and characterized appear to be very diverse, folding almost
exclusively as parallel stranded motifs, thereby limiting the diversity required for
selective targeting. However, although restricted in topology, the G-quadruplex forming
sequences will still contain sequence variability in connecting loops, thus providing new
interaction surfaces and unexpected platforms for interaction. As always, there will be a
need for current (and newly discovered) G-quadruplexes to be validated in terms of
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structure and (more importantly) biological role, before effort is applied to finding
suitable therapeutic agents.
While Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADME-Tox) is a
very important part of medicine design the desired biological target should be of primary
concern when considering design and this has been seriously addressed in the design of
the AIE series. However, possibly one of the most important points in designing a small
molecule drug is the chirality of the target biomolecule or system. The

Figure 15. Axial Chiral Anthracene Isoxazole Ester

idea of using chiral small molecules for the treatment of mammalian diseases is not new,
however, in the case of cancer chemotherapeutics chirality has only recently gained some
consideration.44-45 Chaires and coworkers demonstrated that (+) and (-) enantiomers of
daunorubicin, for which the (+) enantiomer is a known and potent anti-tumor agent
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currently used in general medical practice, selectively bind to different forms of DNA,
B-DNA (Right handed helical) and Z-DNA (Left handed helical) respectively.46 The
inherent chirality of duplex DNA, RNA, and protein α-helices makes these biological
structures ideal targets for chiral small molecules ligands that bind selectively.
Quadruplex DNA structures are right handed helical therefore an antitumor molecule that
would bind selectively to this system must possess the correct element of chirality.
It is proposed that adding an axis of chirality to one of the active compounds in
the AIE series would produce an atropoisomer that should have selectivity for right or left
handed helical DNA based on Chaires findings. In addition, functionalization of the
anthracene, which has some related human toxicity, to somewhat resemble the major
metabolite of anthracene would provide for better bioavailability and decrease the
molecule's potentially toxic character (Figure 15). Though the new system may fall
outside of the Lipinski range it has been shown that the AIE series is also highly active
and therefore the methyl pyrrole can be removed to test the Lipinski prediction. The
outcome of such a comprehensive study of functionality, ADME-Tox, and Chirality for
this AIE series of compounds, as they pertain maximum efficacy in tumor cell
suppression and biomolecule selectivity could be a novel class of antitumor agents that
have little or no side effects. The isoxazole functionality establishes not only a preorganized system for SAR exploration it is the biological handle that is the foundation of
many medicines used in general medical practice today, and therefore should be a potent
contender

in

the

pool

of

small

molecule

antitumor

agents.
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Figure 16. NMR spectrum of 10-Bromoanthracene-9-carbaldehyde
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Figure 17. NMR spectrum of 10-Methoxyanthracene-9-carbaldehyde
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Figure 18. NMR spectrum of 10-Methoxyanthracene-9-carbaldehyde oxime
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Figure 19. NMR spectrum of Ethyl 3-(10-methoxyanthracen-9-yl)-5methylisoxazole-4-carboxylate
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Figure 20. NMR spectrum of Anthracene-9-carbaldehyde oxime
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Figure 21. NMR spectrum of Ethyl 3-(anthracen-9-yl)-5-methylisoxazole-4carboxylate
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Figure 22. NMR spectrum of Ethyl 3-(10-chloroanthracen-9-yl)-5-methylisoxazole4-carboxylate
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Figure 23. NMR spectrum of Ethyl 3-(9-chloro-10-oxo-9,10-dihydroanthracen-9yl)-5-methylisoxazole-4-carboxylate
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Figure 14.

Experimental details
Crystal data
Chemical formula
Mr
Crystal system, space group
Temperature (K)
a, b, c (Å)
α, β, γ (°)
V (Å3)
Z
Radiation type
µ (mm−1)
Crystal size (mm)
Data collection

C43H33Cl2NO8
762.60
Triclinic, P1
100
10.014 (18), 12.57 (2), 14.97 (3)
78.09 (6), 73.36 (3), 89.01 (3)
1765 (6)
2
?, λ = 0.71073 Å
0.24
0.20 × 0.20 × 0.20
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Diffractometer
Absorption correction
Tmin, Tmax
No. of measured,
independent and
observed [I > 2σ(I)]
reflections
Rint
(sin θ/λ)max (Å−1)
Refinement
R[F2 > 2σ(F2)], wR(F2), S
No. of reflections
No. of parameters
No. of restraints
H-atom treatment
(Δ/σ)max
Δρmax, Δρmin (e Å−3)

?
Multi-scan
SADABS V2012/1 (Bruker AXS Inc.)
0.87, 0.95
21846, 8589, 6877

0.030
0.682
0.039, 0.109, 1.11
8589
491
0
H atoms treated by a mixture of independent and
constrained refinement
0.530
0.45, −0.22

Computer programs: SAINT V8.27B (Bruker AXS Inc., 2012), SHELXS97 (Sheldrick,
2008), SHELXL97 (Sheldrick, 2008).
Computing details
Cell refinement: SAINT V8.27B (Bruker AXS Inc., 2012); data reduction: SAINT V8.27B
(Bruker AXS Inc., 2012); program(s) used to solve structure: SHELXS97 (Sheldrick,
2008); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008).
Experimental (I)
Crystal data
C43H33Cl2NO8
Mr = 762.60
Triclinic, P1
a = 10.014 (18) Å
b = 12.57 (2) Å
c = 14.97 (3) Å
α = 78.09 (6)°
β = 73.36 (3)°

Z=2
F(000) = 792
Dx = 1.436 Mg m−3
? radiation, λ = 0.71073 Å
Cell parameters from 9917
reflections
θ = 2.2–28.8°
µ = 0.24 mm−1
T = 100 K
53

γ = 89.01 (3)°
V = 1765 (6) Å3

Prism
0.20 × 0.20 × 0.20 mm

Data collection
Detector resolution: 8.3333 pixels
mm-1
Absorption correction: multi-scan
SADABS V2012/1 (Bruker AXS
Inc.)
Tmin = 0.87, Tmax = 0.95
21846 measured reflections
8589 independent reflections
6877 reflections with I > 2σ(I)

Rint = 0.030
θmax = 29.0°, θmin = 1.5°
h = −13→13
k = −17→16
l = −20→20

Refinement
Refinement on F2
Least-squares matrix: full
R[F2 > 2σ(F2)] = 0.039
wR(F2) = 0.109
S = 1.11
8589 reflections
491 parameters
0 restraints

Primary atom site location:
structure-invariant direct methods
Secondary atom site location:
difference Fourier map
Hydrogen site location: inferred
from neighbouring sites
H atoms treated by a mixture of
independent and constrained
refinement
w = 1/[σ2(Fo2) + (0.060P)2]
where P = (Fo2 + 2Fc2)/3
(Δ/σ)max = 0.530
Δρmax = 0.45 e Å−3
Δρmin = −0.22 e Å−3

Special details
Refinement
Refinement of F2 against ALL reflections. The weighted R-factor wR and goodness of fit
S are based on F2, conventional R-factors R are based on F, with F set to zero for
negative F2. The threshold expression of F2 > σ(F2) is used only for calculating Rfactors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors
based on F2 are statistically about twice as large as those based on F, and R- factors based
on ALL data will be even larger.
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Fractional atomic coordinates and isotropic or equivalent isotropic displacement
parameters (Å2)
x
y
z
Uiso*/Ueq
Cl1 0.39467 (4)
−0.13787 (3)
0.41774 (3)
0.01734 (10)
Cl2 0.89937 (4)
0.66479 (3)
0.42670 (3)
0.01629 (9)
C1
0.35916 (16)
−0.16673 (12)
0.21644 (11)
0.0170 (3)
H1
0.2771
−0.2021
0.2618
0.02*
C2
0.41980 (16)
−0.20648 (13)
0.13527 (11)
0.0194 (3)
H2
0.3805
−0.2701
0.1259
0.023*
C3
0.53801 (16)
−0.15387 (13)
0.06732 (11)
0.0190 (3)
H3
0.5781
−0.1805
0.011
0.023*
C4
0.59699 (16)
−0.06301 (13)
0.08184 (11)
0.0169 (3)
H4
0.6778
−0.0272
0.0353
0.02*
C5
0.59779 (16)
0.20976 (12)
0.27859 (11)
0.0156 (3)
H5
0.6837
0.241
0.2352
0.019*
C6
0.53337 (16)
0.25573 (12)
0.35502 (11)
0.0176 (3)
H6
0.5753
0.3179
0.3648
0.021*
C7
0.40673 (17)
0.21076 (13)
0.41786 (11)
0.0186 (3)
H7
0.3609
0.2435
0.4697
0.022*
C8
0.34743 (16)
0.11879 (12)
0.40524 (11)
0.0161 (3)
H8
0.261
0.0884
0.4485
0.019*
C9
0.35237 (15)
−0.03612 (11)
0.32323 (10)
0.0119 (3)
C10 0.60597 (15)
0.07311 (12)
0.17908 (10)
0.0136 (3)
C11 0.53872 (15)
−0.02303 (12)
0.16456 (10)
0.0124 (3)
C12 0.41784 (15)
−0.07508 (11)
0.23187 (10)
0.0121 (3)
C13 0.41347 (15)
0.07022 (11)
0.32949 (10)
0.0113 (3)
C14 0.53782 (15)
0.11751 (11)
0.26438 (10)
0.0119 (3)
C15 0.19528 (15)
−0.03352 (11)
0.34531 (10)
0.0119 (3)
C16 0.11564 (15)
0.03388 (12)
0.29156 (10)
0.0124 (3)
C17 −0.01974 (15)
0.00798 (12)
0.34468 (10)
0.0135 (3)
C18 −0.15775 (15)
0.04669 (13)
0.33728 (12)
0.0197 (3)
H9
−0.2266
−0.0146
0.3613
0.029*
H11 −0.1511
0.0779
0.2704
0.029*
H10 −0.1867
0.1024
0.3753
0.029*
C19 0.17127 (15)
0.11453 (12)
0.20198 (10)
0.0132 (3)
C20 0.11554 (16)
0.25119 (13)
0.08400 (11)
0.0188 (3)
H12 0.1443
0.2184
0.027
0.023*
H13 0.1957
0.2949
0.0857
0.023*
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C21
H14
H16
H15
C22
H17
C23
H18
C24
H19
C25
H20
C26
H21
C27
H22
C28
H23
C29
H24
C30
C31
C32
C33
C34
C35
C36
C37
C38
C39
H25
H27
H26
C40
C41
H28
H29
C42

−0.00676 (17)
−0.0875
0.0173
−0.0296
0.85760 (16)
0.7694
0.92109 (16)
0.8765
1.05042 (17)
1.0961
1.11295 (16)
1.2003
1.10150 (15)
1.1859
1.03694 (16)
1.0771
0.91269 (16)
0.868
0.85343 (16)
0.7676
0.85690 (15)
1.11608 (15)
1.04862 (15)
0.92176 (15)
0.91894 (15)
1.04392 (15)
0.69982 (15)
0.62199 (15)
0.48620 (15)
0.34938 (15)
0.321
0.3573
0.2794
0.68012 (15)
0.63080 (16)
0.708
0.6647
0.50717 (16)

0.32187 (13)
0.2767
0.3767
0.3582
0.41858 (12)
0.4256
0.32023 (12)
0.2597
0.31006 (12)
0.2433
0.39706 (12)
0.3891
0.77518 (12)
0.7652
0.87226 (13)
0.9295
0.88644 (12)
0.9536
0.80285 (12)
0.8127
0.61725 (11)
0.58694 (12)
0.49630 (12)
0.50795 (11)
0.70497 (12)
0.69082 (11)
0.60498 (11)
0.56608 (11)
0.56731 (11)
0.53651 (13)
0.462
0.5406
0.5866
0.53118 (12)
0.44355 (13)
0.3939
0.5049
0.38379 (13)

0.08050 (12)
0.0838
0.0208
0.1347
0.40063 (10)
0.444
0.40860 (11)
0.457
0.34561 (11)
0.3525
0.27278 (11)
0.2288
0.09529 (11)
0.0493
0.08403 (11)
0.0309
0.15061 (11)
0.143
0.22823 (11)
0.2729
0.32927 (10)
0.18297 (10)
0.26351 (10)
0.32941 (10)
0.24094 (10)
0.17394 (10)
0.35216 (10)
0.29806 (10)
0.35019 (10)
0.34072 (11)
0.3767
0.2733
0.3659
0.20702 (10)
0.09360 (10)
0.0965
0.0383
0.08488 (11)

0.0206 (3)
0.031*
0.031*
0.031*
0.0152 (3)
0.018*
0.0174 (3)
0.021*
0.0177 (3)
0.021*
0.0152 (3)
0.018*
0.0150 (3)
0.018*
0.0185 (3)
0.022*
0.0189 (3)
0.023*
0.0164 (3)
0.02*
0.0113 (3)
0.0131 (3)
0.0123 (3)
0.0116 (3)
0.0120 (3)
0.0119 (3)
0.0109 (3)
0.0129 (3)
0.0131 (3)
0.0184 (3)
0.028*
0.028*
0.028*
0.0127 (3)
0.0161 (3)
0.019*
0.019*
0.0185 (3)
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H30
H31
H32
N1
N2
O1
O2
O3
O4
O5
O6
O7
O8

0.4796
0.5326
0.4291
0.11438 (12)
0.61807 (12)
0.71551 (11)
−0.02303 (10)
0.29466 (11)
0.07022 (11)
1.22729 (11)
0.48084 (10)
0.80195 (11)
0.58166 (10)

0.32
0.3602
0.4323
−0.09462 (10)
0.62767 (10)
0.11532 (9)
−0.06859 (8)
0.13287 (9)
0.16608 (9)
0.57605 (9)
0.60448 (8)
0.54218 (9)
0.48367 (9)

0.1374
0.0239
0.0876
0.42317 (9)
0.43052 (9)
0.12176 (8)
0.42289 (7)
0.16269 (7)
0.17063 (7)
0.12509 (8)
0.42934 (7)
0.16192 (7)
0.18180 (7)

0.028*
0.028*
0.028*
0.0147 (3)
0.0141 (3)
0.0213 (3)
0.0161 (2)
0.0192 (2)
0.0180 (2)
0.0203 (2)
0.0149 (2)
0.0191 (2)
0.0159 (2)

Atomic displacement parameters (Å2)
U11

U22

U33

U12

U13

U23

Cl1 0.01769 (19) 0.01571 (18) 0.01612 (19) 0.00367 (14) −0.00459 (15) 0.00155 (14)
Cl2 0.01699 (19) 0.01912 (19) 0.01480 (18) −0.00256 (14) −0.00484 (14) −0.00744 (14)
C1 0.0149 (8) 0.0155 (7) 0.0189 (8) −0.0018 (6) −0.0008 (6) −0.0052 (6)
C2 0.0187 (8) 0.0180 (8) 0.0246 (8) 0.0008 (6)
−0.0065 (7) −0.0109 (7)
C3 0.0176 (8) 0.0238 (8) 0.0177 (8) 0.0046 (6)
−0.0035 (6) −0.0117 (7)
C4 0.0139 (7) 0.0195 (8) 0.0158 (8) 0.0015 (6)
−0.0017 (6) −0.0042 (6)
C5 0.0151 (7) 0.0121 (7) 0.0196 (8) −0.0004 (6) −0.0066 (6) −0.0010 (6)
C6 0.0223 (8) 0.0120 (7) 0.0230 (8) 0.0006 (6)
−0.0116 (7) −0.0065 (6)
C7 0.0215 (8) 0.0196 (8) 0.0177 (8) 0.0053 (6)
−0.0073 (7) −0.0089 (6)
C8 0.0151 (8) 0.0183 (8) 0.0143 (7) 0.0018 (6)
−0.0031 (6) −0.0042 (6)
C9 0.0116 (7) 0.0113 (7) 0.0114 (7) 0.0018 (5)
−0.0026 (6) 0.0000 (5)
C10 0.0123 (7) 0.0125 (7) 0.0145 (7) 0.0019 (6)
−0.0033 (6) −0.0006 (6)
C11 0.0111 (7) 0.0125 (7) 0.0133 (7) 0.0025 (5)
−0.0032 (6) −0.0026 (6)
C12 0.0122 (7) 0.0111 (7) 0.0125 (7) 0.0034 (5)
−0.0028 (6) −0.0029 (6)
C13 0.0117 (7) 0.0106 (7) 0.0126 (7) 0.0022 (5)
−0.0051 (6) −0.0024 (5)
C14 0.0115 (7) 0.0098 (7) 0.0143 (7) 0.0029 (5)
−0.0048 (6) −0.0011 (6)
C15 0.0137 (7) 0.0094 (7) 0.0118 (7) 0.0010 (5)
−0.0014 (6) −0.0039 (5)
C16 0.0118 (7) 0.0123 (7) 0.0134 (7) 0.0007 (6)
−0.0030 (6) −0.0041 (6)
C17 0.0156 (7) 0.0102 (7) 0.0145 (7) −0.0009 (6) −0.0035 (6) −0.0032 (6)
C18 0.0116 (7) 0.0235 (8) 0.0230 (8) 0.0019 (6)
−0.0029 (6) −0.0058 (7)
C19 0.0132 (7) 0.0142 (7) 0.0133 (7) 0.0025 (6)
−0.0044 (6) −0.0051 (6)
C20 0.0188 (8) 0.0200 (8) 0.0142 (7) 0.0008 (6)
−0.0039 (6) 0.0029 (6)
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C21 0.0203 (8)
C22 0.0156 (7)
C23 0.0227 (8)
C24 0.0229 (8)
C25 0.0133 (7)
C26 0.0118 (7)
C27 0.0184 (8)
C28 0.0193 (8)
C29 0.0140 (7)
C30 0.0119 (7)
C31 0.0119 (7)
C32 0.0120 (7)
C33 0.0126 (7)
C34 0.0117 (7)
C35 0.0117 (7)
C36 0.0123 (7)
C37 0.0140 (7)
C38 0.0155 (7)
C39 0.0121 (7)
C40 0.0135 (7)
C41 0.0155 (8)
C42 0.0187 (8)
N1 0.0097 (6)
N2 0.0099 (6)
O1 0.0176 (6)
O2 0.0099 (5)
O3 0.0133 (5)
O4 0.0131 (5)
O5 0.0156 (6)
O6 0.0107 (5)
O7 0.0139 (5)
O8 0.0132 (5)

0.0210 (8)
0.0153 (7)
0.0126 (7)
0.0111 (7)
0.0156 (7)
0.0176 (7)
0.0165 (8)
0.0131 (7)
0.0144 (7)
0.0125 (7)
0.0142 (7)
0.0119 (7)
0.0112 (7)
0.0113 (7)
0.0113 (7)
0.0076 (6)
0.0108 (7)
0.0103 (7)
0.0230 (8)
0.0132 (7)
0.0219 (8)
0.0209 (8)
0.0147 (6)
0.0147 (6)
0.0192 (6)
0.0159 (5)
0.0226 (6)
0.0197 (6)
0.0189 (6)
0.0171 (5)
0.0273 (6)
0.0222 (6)

0.0210 (8)
0.0133 (7)
0.0162 (7)
0.0229 (8)
0.0183 (8)
0.0148 (7)
0.0169 (8)
0.0234 (8)
0.0188 (8)
0.0104 (7)
0.0148 (7)
0.0147 (7)
0.0125 (7)
0.0134 (7)
0.0129 (7)
0.0117 (7)
0.0130 (7)
0.0130 (7)
0.0196 (8)
0.0111 (7)
0.0126 (7)
0.0186 (8)
0.0171 (6)
0.0164 (6)
0.0212 (6)
0.0190 (6)
0.0171 (6)
0.0170 (6)
0.0210 (6)
0.0167 (5)
0.0168 (6)
0.0144 (5)

0.0042 (7)
−0.0022 (6)
−0.0032 (6)
0.0039 (6)
0.0006 (6)
−0.0026 (6)
−0.0033 (6)
0.0017 (6)
0.0008 (6)
−0.0005 (5)
−0.0013 (6)
−0.0016 (5)
−0.0013 (5)
−0.0027 (5)
−0.0023 (5)
−0.0002 (5)
−0.0009 (6)
0.0000 (6)
−0.0010 (6)
0.0000 (6)
0.0019 (6)
0.0002 (6)
0.0007 (5)
−0.0025 (5)
−0.0062 (5)
−0.0005 (4)
0.0014 (4)
0.0005 (4)
0.0003 (4)
0.0003 (4)
−0.0021 (5)
−0.0010 (4)

−0.0087 (7)
−0.0028 (6)
−0.0075 (6)
−0.0121 (7)
−0.0051 (6)
−0.0029 (6)
−0.0038 (6)
−0.0066 (7)
−0.0014 (6)
−0.0028 (6)
−0.0047 (6)
−0.0057 (6)
−0.0058 (6)
−0.0042 (6)
−0.0039 (6)
−0.0021 (6)
−0.0032 (6)
−0.0040 (6)
−0.0039 (6)
−0.0042 (6)
−0.0041 (6)
−0.0074 (6)
−0.0008 (5)
−0.0012 (5)
0.0043 (5)
−0.0004 (4)
−0.0021 (4)
−0.0036 (4)
0.0031 (5)
−0.0017 (4)
−0.0019 (4)
−0.0038 (4)

−0.0019 (7)
−0.0016 (6)
0.0014 (6)
−0.0046 (6)
−0.0066 (6)
−0.0023 (6)
0.0030 (6)
−0.0011 (6)
−0.0035 (6)
−0.0047 (6)
−0.0050 (6)
−0.0040 (6)
−0.0029 (6)
−0.0026 (6)
−0.0025 (6)
−0.0012 (5)
−0.0016 (6)
−0.0012 (6)
−0.0043 (7)
−0.0012 (6)
−0.0073 (6)
−0.0074 (6)
−0.0021 (5)
−0.0040 (5)
−0.0048 (5)
−0.0012 (4)
0.0030 (5)
0.0045 (4)
−0.0039 (5)
−0.0061 (4)
−0.0097 (5)
−0.0084 (4)

Geometric parameters (Å, º)
Cl1—C9
Cl2—C30
C1—C2
C1—C12

1.842 (3)
1.840 (3)
1.383 (3)
1.391 (3)

C22—C23
C22—C33
C22—H17
C23—C24

1.379 (3)
1.396 (3)
0.95
1.388 (3)
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C1—H1
C2—C3
C2—H2
C3—C4
C3—H3
C4—C11
C4—H4
C5—C6
C5—C14
C5—H5
C6—C7
C6—H6
C7—C8
C7—H7
C8—C13
C8—H8
C9—C13
C9—C15
C9—C12
C10—O1
C10—C11
C10—C14
C11—C12
C13—C14
C15—N1
C15—C16
C16—C17
C16—C19
C17—O2
C17—C18
C18—H9
C18—H11
C18—H10
C19—O3
C19—O4
C20—O4
C20—C21
C20—H12

0.95
1.390 (3)
0.95
1.378 (3)
0.95
1.399 (3)
0.95
1.377 (3)
1.396 (3)
0.95
1.391 (3)
0.95
1.379 (3)
0.95
1.392 (3)
0.95
1.511 (3)
1.513 (3)
1.514 (3)
1.230 (2)
1.477 (3)
1.479 (3)
1.402 (3)
1.395 (3)
1.310 (3)
1.436 (3)
1.366 (3)
1.472 (3)
1.346 (3)
1.484 (3)
0.98
0.98
0.98
1.210 (3)
1.337 (2)
1.462 (3)
1.507 (3)
0.99

C23—H18
C24—C25
C24—H19
C25—C32
C25—H20
C26—C27
C26—C35
C26—H21
C27—C28
C27—H22
C28—C29
C28—H23
C29—C34
C29—H24
C30—C33
C30—C36
C30—C34
C31—O5
C31—C35
C31—C32
C32—C33
C34—C35
C36—N2
C36—C37
C37—C38
C37—C40
C38—O6
C38—C39
C39—H25
C39—H27
C39—H26
C40—O7
C40—O8
C41—O8
C41—C42
C41—H28
C41—H29
C42—H30

0.95
1.385 (3)
0.95
1.394 (3)
0.95
1.373 (3)
1.400 (3)
0.95
1.389 (3)
0.95
1.389 (3)
0.95
1.388 (3)
0.95
1.509 (3)
1.514 (3)
1.517 (3)
1.225 (2)
1.482 (3)
1.483 (3)
1.394 (3)
1.397 (3)
1.307 (3)
1.428 (3)
1.362 (3)
1.474 (3)
1.347 (3)
1.483 (3)
0.98
0.98
0.98
1.208 (3)
1.341 (2)
1.460 (3)
1.510 (3)
0.99
0.99
0.98
59

C20—H13
C21—H14
C21—H16
C21—H15
C2—C1—C12
C2—C1—H1
C12—C1—H1
C1—C2—C3
C1—C2—H2
C3—C2—H2
C4—C3—C2
C4—C3—H3
C2—C3—H3
C3—C4—C11
C3—C4—H4
C11—C4—H4
C6—C5—C14
C6—C5—H5
C14—C5—H5
C5—C6—C7
C5—C6—H6
C7—C6—H6
C8—C7—C6
C8—C7—H7
C6—C7—H7
C7—C8—C13
C7—C8—H8
C13—C8—H8
C13—C9—C15
C13—C9—C12
C15—C9—C12
C13—C9—Cl1
C15—C9—Cl1
C12—C9—Cl1
O1—C10—C11
O1—C10—C14
C11—C10—C14
C4—C11—C12

0.99
0.98
0.98
0.98
120.24 (16)
119.9
119.9
120.34 (17)
119.8
119.8
119.90 (17)
120.1
120.1
120.51 (16)
119.7
119.7
120.48 (17)
119.8
119.8
119.76 (16)
120.1
120.1
120.24 (16)
119.9
119.9
120.39 (17)
119.8
119.8
110.92 (13)
115.38 (14)
111.79 (13)
104.50 (15)
108.42 (11)
105.19 (16)
120.96 (16)
120.87 (16)
118.17 (15)
119.32 (16)

C42—H31
C42—H32
N1—O2
N2—O6
C22—C23—C24
C22—C23—H18
C24—C23—H18
C25—C24—C23
C25—C24—H19
C23—C24—H19
C24—C25—C32
C24—C25—H20
C32—C25—H20
C27—C26—C35
C27—C26—H21
C35—C26—H21
C26—C27—C28
C26—C27—H22
C28—C27—H22
C27—C28—C29
C27—C28—H23
C29—C28—H23
C34—C29—C28
C34—C29—H24
C28—C29—H24
C33—C30—C36
C33—C30—C34
C36—C30—C34
C33—C30—Cl2
C36—C30—Cl2
C34—C30—Cl2
O5—C31—C35
O5—C31—C32
C35—C31—C32
C25—C32—C33
C25—C32—C31
C33—C32—C31
C32—C33—C22

0.98
0.98
1.410 (3)
1.415 (3)
119.75 (16)
120.1
120.1
120.12 (16)
119.9
119.9
120.44 (17)
119.8
119.8
120.53 (17)
119.7
119.7
119.75 (16)
120.1
120.1
120.30 (17)
119.9
119.9
120.37 (17)
119.8
119.8
110.70 (14)
115.52 (15)
111.86 (12)
104.31 (12)
108.80 (11)
105.01 (16)
120.93 (15)
121.13 (16)
117.94 (16)
119.39 (15)
119.16 (17)
121.44 (15)
119.57 (16)
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C4—C11—C10
C12—C11—C10
C1—C12—C11
C1—C12—C9
C11—C12—C9
C8—C13—C14
C8—C13—C9
C14—C13—C9
C13—C14—C5
C13—C14—C10
C5—C14—C10
N1—C15—C16
N1—C15—C9
C16—C15—C9
C17—C16—C15
C17—C16—C19
C15—C16—C19
O2—C17—C16
O2—C17—C18
C16—C17—C18
C17—C18—H9
C17—C18—H11
H9—C18—H11
C17—C18—H10
H9—C18—H10
H11—C18—H10
O3—C19—O4
O3—C19—C16
O4—C19—C16
O4—C20—C21
O4—C20—H12
C21—C20—H12
O4—C20—H13
C21—C20—H13
H12—C20—H13
C20—C21—H14
C20—C21—H16
H14—C21—H16

119.27 (15)
121.40 (16)
119.66 (16)
119.01 (15)
121.29 (15)
119.44 (16)
118.83 (15)
121.65 (15)
119.61 (16)
121.15 (15)
119.23 (15)
111.56 (18)
120.59 (14)
127.80 (14)
103.98 (17)
129.32 (14)
126.66 (16)
109.47 (15)
115.27 (13)
135.22 (17)
109.5
109.5
109.5
109.5
109.5
109.5
124.32 (17)
123.36 (14)
112.31 (16)
107.02 (15)
110.3
110.3
110.3
110.3
108.6
109.5
109.5
109.5

C32—C33—C30
C22—C33—C30
C29—C34—C35
C29—C34—C30
C35—C34—C30
C34—C35—C26
C34—C35—C31
C26—C35—C31
N2—C36—C37
N2—C36—C30
C37—C36—C30
C38—C37—C36
C38—C37—C40
C36—C37—C40
O6—C38—C37
O6—C38—C39
C37—C38—C39
C38—C39—H25
C38—C39—H27
H25—C39—H27
C38—C39—H26
H25—C39—H26
H27—C39—H26
O7—C40—O8
O7—C40—C37
O8—C40—C37
O8—C41—C42
O8—C41—H28
C42—C41—H28
O8—C41—H29
C42—C41—H29
H28—C41—H29
C41—C42—H30
C41—C42—H31
H30—C42—H31
C41—C42—H32
H30—C42—H32
H31—C42—H32

121.18 (14)
119.13 (17)
119.27 (15)
119.49 (16)
121.19 (15)
119.78 (16)
121.35 (15)
118.86 (16)
111.56 (18)
120.83 (14)
127.58 (15)
104.65 (18)
129.08 (14)
126.26 (17)
109.06 (15)
115.39 (13)
135.54 (17)
109.5
109.5
109.5
109.5
109.5
109.5
124.38 (17)
123.99 (14)
111.61 (16)
106.17 (14)
110.5
110.5
110.5
110.5
108.7
109.5
109.5
109.5
109.5
109.5
109.5
61

C20—C21—H15
H14—C21—H15
H16—C21—H15
C23—C22—C33
C23—C22—H17
C33—C22—H17
C12—C1—C2—C3
C1—C2—C3—C4
C2—C3—C4—C11
C14—C5—C6—C7
C5—C6—C7—C8
C6—C7—C8—C13
C3—C4—C11—C12
C3—C4—C11—C10
O1—C10—C11—C4
C14—C10—C11—C4
O1—C10—C11—C12
C14—C10—C11—C12
C2—C1—C12—C11
C2—C1—C12—C9
C4—C11—C12—C1
C10—C11—C12—C1
C4—C11—C12—C9
C10—C11—C12—C9
C13—C9—C12—C1
C15—C9—C12—C1
Cl1—C9—C12—C1
C13—C9—C12—C11
C15—C9—C12—C11
Cl1—C9—C12—C11
C7—C8—C13—C14
C7—C8—C13—C9
C15—C9—C13—C8
C12—C9—C13—C8
Cl1—C9—C13—C8
C15—C9—C13—C14
C12—C9—C13—C14
Cl1—C9—C13—C14

109.5
109.5
109.5
120.64 (18)
119.7
119.7
−1.5 (2)
1.4 (2)
−0.1 (2)
−0.8 (2)
1.7 (2)
−0.1 (2)
−1.3 (2)
178.72 (14)
−3.3 (2)
176.57 (13)
176.69 (14)
−3.4 (2)
0.1 (2)
−177.61 (14)
1.2 (2)
−178.76 (13)
178.92 (13)
−1.1 (2)
−173.93 (13)
−45.95 (19)
71.50 (19)
8.36 (19)
136.33 (15)
−106.21 (18)
−2.3 (2)
174.37 (13)
43.18 (18)
171.59 (13)
−73.44 (19)
−140.27 (15)
−11.87 (19)
103.10 (19)

C15—N1—O2
C36—N2—O6
C17—O2—N1
C19—O4—C20
C38—O6—N2
C40—O8—C41
O5—C31—C32—C25
C35—C31—C32—C25
O5—C31—C32—C33
C35—C31—C32—C33
C25—C32—C33—C22
C31—C32—C33—C22
C25—C32—C33—C30
C31—C32—C33—C30
C23—C22—C33—C32
C23—C22—C33—C30
C36—C30—C33—C32
C34—C30—C33—C32
Cl2—C30—C33—C32
C36—C30—C33—C22
C34—C30—C33—C22
Cl2—C30—C33—C22
C28—C29—C34—C35
C28—C29—C34—C30
C33—C30—C34—C29
C36—C30—C34—C29
Cl2—C30—C34—C29
C33—C30—C34—C35
C36—C30—C34—C35
Cl2—C30—C34—C35
C29—C34—C35—C26
C30—C34—C35—C26
C29—C34—C35—C31
C30—C34—C35—C31
C27—C26—C35—C34
C27—C26—C35—C31
O5—C31—C35—C34
C32—C31—C35—C34

105.50 (15)
105.34 (15)
109.49 (11)
116.30 (15)
109.39 (11)
115.37 (14)
−0.4 (2)
178.88 (13)
−179.71 (14)
−0.4 (2)
−3.3 (2)
176.02 (13)
172.62 (13)
−8.1 (2)
2.5 (2)
−173.48 (13)
142.29 (15)
13.87 (19)
−100.84 (19)
−41.77 (19)
−170.19 (13)
75.1 (2)
−1.1 (2)
176.39 (14)
170.70 (13)
42.85 (19)
−74.99 (18)
−11.90 (19)
−139.74 (15)
102.41 (17)
0.2 (2)
−177.26 (13)
−178.46 (13)
4.1 (2)
0.8 (2)
179.40 (14)
−178.32 (14)
2.4 (2)
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C8—C13—C14—C5
C9—C13—C14—C5
C8—C13—C14—C10
C9—C13—C14—C10
C6—C5—C14—C13
C6—C5—C14—C10
O1—C10—C14—C13
C11—C10—C14—C13
O1—C10—C14—C5
C11—C10—C14—C5
C13—C9—C15—N1
C12—C9—C15—N1
Cl1—C9—C15—N1
C13—C9—C15—C16
C12—C9—C15—C16
Cl1—C9—C15—C16
N1—C15—C16—C17
C9—C15—C16—C17
N1—C15—C16—C19
C9—C15—C16—C19
C15—C16—C17—O2
C19—C16—C17—O2
C15—C16—C17—C18
C19—C16—C17—C18
C17—C16—C19—O3
C15—C16—C19—O3
C17—C16—C19—O4
C15—C16—C19—O4
C33—C22—C23—C24
C22—C23—C24—C25
C23—C24—C25—C32
C35—C26—C27—C28
C26—C27—C28—C29
C27—C28—C29—C34
C24—C25—C32—C33
C24—C25—C32—C31

3.1 (2)
−173.44 (13)
−175.52 (13)
8.0 (2)
−1.6 (2)
177.06 (13)
179.83 (13)
0.0 (2)
1.2 (2)
−178.63 (13)
−111.82 (19)
117.9 (2)
2.37 (17)
65.4 (2)
−64.9 (2)
179.60 (12)
0.40 (16)
−177.04 (14)
178.26 (14)
0.8 (2)
−0.56 (16)
−178.34 (14)
176.92 (17)
−0.9 (3)
177.55 (15)
0.2 (2)
−1.2 (2)
−178.51 (13)
0.4 (2)
−2.5 (2)
1.7 (2)
−0.7 (2)
−0.2 (2)
1.1 (2)
1.2 (2)
−178.12 (13)

O5—C31—C35—C26
C32—C31—C35—C26
C33—C30—C36—N2
C34—C30—C36—N2
Cl2—C30—C36—N2
C33—C30—C36—C37
C34—C30—C36—C37
Cl2—C30—C36—C37
N2—C36—C37—C38
C30—C36—C37—C38
N2—C36—C37—C40
C30—C36—C37—C40
C36—C37—C38—O6
C40—C37—C38—O6
C36—C37—C38—C39
C40—C37—C38—C39
C38—C37—C40—O7
C36—C37—C40—O7
C38—C37—C40—O8
C36—C37—C40—O8
C16—C15—N1—O2
C9—C15—N1—O2
C37—C36—N2—O6
C30—C36—N2—O6
C16—C17—O2—N1
C18—C17—O2—N1
C15—N1—O2—C17
O3—C19—O4—C20
C16—C19—O4—C20
C21—C20—O4—C19
C37—C38—O6—N2
C39—C38—O6—N2
C36—N2—O6—C38
O7—C40—O8—C41
C37—C40—O8—C41
C42—C41—O8—C40

3.1 (2)
−176.20 (13)
114.47 (16)
−115.2 (2)
0.40 (17)
−63.2 (2)
67.1 (2)
−177.30 (12)
0.10 (16)
177.98 (13)
−178.89 (13)
−1.0 (2)
0.37 (16)
179.32 (13)
−178.35 (16)
0.6 (3)
173.17 (15)
−8.1 (2)
−8.2 (2)
170.51 (13)
−0.08 (15)
177.56 (12)
−0.50 (15)
−178.54 (11)
0.55 (16)
−177.50 (12)
−0.28 (15)
−1.2 (2)
177.50 (12)
−161.22 (13)
−0.69 (15)
178.32 (12)
0.73 (14)
0.3 (2)
−178.28 (12)
174.26 (12)
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